Beyond Inertia: Advancing T2D Care with Innovative Basal Insulin Strategies-Beyond Inertia: Advancing T2D Care with Innovative Basal Insulin Strategies

Beyond Inertia: Advancing T2D Care with Innovative Basal Insulin Strategies

Video Transcription

Video Summary

In summary, the video discussed the introduction of new once-weekly basal insulin options for the treatment of diabetes, such as insulin ecotec and insulin f-citora. These novel insulins aim to simplify treatment regimens, improve glycemic control, and reduce the burden of insulin therapy for patients. Clinical trials have shown that these once-weekly insulins provide comparable or even superior reductions in A1c levels, time in range, and lower rates of hypoglycemia compared to daily insulin regimens. Patient preferences for once-weekly insulin therapy are high, with many expressing interest in the convenience and potential benefits of less frequent injections. The insulins have also been shown to be safe and well-tolerated, offering a promising option for patients to achieve their glycemic goals and improve their overall diabetes management.

Keywords

once-weekly basal insulin

insulin ecotec

insulin f-citora

diabetes treatment

glycemic control

clinical trials

A1c levels

hypoglycemia

patient preferences

diabetes management


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274